Oncology bonanza as Japan lists new drugs
This article was originally published in Scrip
Japan has added a total of 22 drug active ingredients to the national health insurance reimbursement tariff, including several novel products for cancer indications that will see their first launches worldwide.
You may also be interested in...
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.